Investigational drug · Phase 3
ZN-A-1041
Also called: ZN-A-1041 Enteric, RO7771950, RG6596
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Breast Cancer, Advanced Solid Tumors.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ZN-A-1041"
First trial start
2020
Sep 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZN-A-1041", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Breast Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ZN-A-1041" as an intervention, largest first.
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositivePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07413939 · 650 participants (planned) · Start May 21, 2026 · Primary completion May 1, 2029
Drug: RO7771950; Tucatinib and 2 more · For: HER2-positive Breast Cancer
Sites: Huntsville, Alabama; Gilbert, Arizona; Clovis, California · 219 sites in all
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05593094 · 210 participants (planned) · Start Sep 3, 2020 · Primary completion Aug 31, 2027
Drug: ZN-A-1041; ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b and 5 more · For: Advanced Solid Tumors; HER2-positive Breast Cancer
Sites: Tucson, Arizona; Cerritos, California; San Francisco, California · 36 sites in all
Suzhou Zanrong Pharma LimitedIndustry
NCT04487236 · 61 participants · Start Oct 15, 2020 · Primary completion Apr 16, 2024
Drug: ZN-A-1041 50mg BID; ZN-A-1041 100mg BID and 9 more · For: Advanced Solid Tumors; HER2-positive Breast Cancer
Sites: Beijing, China
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07329972 · 24 participants · Start Nov 21, 2025 · Primary completion Dec 14, 2025
Drug: ZN-A-1041 Formulation 1; ZN-A-1041 Formulation 2 and 1 more · For: Healthy Volunteers
Sites: Daytona Beach, Florida; Dallas, Texas
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07051993 · 18 participants · Start Jun 27, 2025 · Primary completion Jul 12, 2025
Drug: ZN-A-1041 · For: Healthy Participants
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HER2-positive Breast Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- GQ1005Phase 31 trial
GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.